Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
30Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04672928CT.gov A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ibi318 (this asset) | Innovent Biologics (Suzhou) Co. Ltd. | P1 | CC · 43 |
| Benmelstobart | Yayi He | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Nogitecan | AbbVie | P4 | BB |
| Irinotecan | Sichuan University | P4 | BB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for ibi318
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Extranodal Nasal NK/T Cell Lymphoma | — | P1/2 | CC · 46 |
| Non-Small Cell Lung Carcinoma | — | P2 | CC · 40 |
| Hepatocellular Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ibi318 in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/ibi318-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →